Stay updated on Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page.

Latest updates to the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page
- Check2 days agoChange DetectedEnrollment is updated to 959 participants and the study's last update is posted on 2025-08-11. Primary completion is 2025-03-20 and estimated study completion is 2025-09-30.SummaryDifference0.1%

 - Check10 days agoNo Change Detected
 - Check31 days agoChange DetectedDifference1%

 - Check38 days agoChange DetectedPage content is updated to revision v3.1.0 and several MedlinePlus topics are removed; overall, no substantial new information is added and core content remains unchanged.SummaryDifference0.2%

 - Check53 days agoChange DetectedMinor update: version bumped from v3.0.1 to v3.0.2 and the Back to Top element was removed; core content remains unchanged.SummaryDifference0.1%

 - Check60 days agoChange DetectedThe location name has been updated from 'Tuen Mun, Hong Kong' to 'Tuenmen, Hong Kong', and the version number has changed from v3.0.0 to v3.0.1.SummaryDifference0.1%

 - Check67 days agoChange DetectedThe webpage has undergone significant updates, including the addition of numerous location details across various countries, particularly in Europe, Asia, and South America, as well as the introduction of new medical topics related to drug safety. Several outdated location entries have been removed, streamlining the content.SummaryDifference23%

 
Stay in the know with updates to Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page.